Portcullis Surgery

Portcullis Surgery

Portcullis Lane, Ludlow, SY8 1GT

Current time is 02:02 - Sorry, we're closed

NHS

Telephone: 01584 872 939

Fax: 01584 879 031

portcullis.surgery@nhs.net

Update on Covid Vaccine (23.11.2020)

 

Update on 23.11.2020

Following clinical trials, a Covid-19 vaccine developed by the University of Oxford in collaboration with AstraZeneca has proven to be effective. While the preliminary data suggests that the vaccine prevents 70% of infections, it could prevent up to 90% of infections, depending on how the vaccine is administered. There were no hospitalisations or severe cases of the disease amongst those who received the vaccine. Crucially, the vaccine can be easily administered in existing healthcare systems, as it can be stored at fridge temperature (2-8 °C). The full safety data and findings will need to be peer reviewed before a vaccine can be approved for use.
If approved, up to 3 billion doses could be manufactured in 2021. The vaccine will be provided on a not-for-profit basis for the duration of the pandemic, and in perpetuity to low- and middle-income countries.
The UK government is supporting the development and fair distribution of a coronavirus vaccine through the COVAX facility. This ensures we have the best chance of accessing a safe and effective vaccine for people in the UK as soon as one becomes available, as well as supporting access in poorer countries.
For information look up the following link:

https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine?fbclid=IwAR0vAwU86lLIH63q86Z5XWqFD8-wju9f_trGQoJ2y9hLEI5nJqxcDy1Qi8k

Update on 18.11.2020

Last week, Pfizer and BioNTech published preliminary data showing the vaccine offered 90% protection against Covid-19 and there were no safety concerns. This has been followed by impressive data on another vaccine, made by US company Moderna, suggesting nearly 95% protection.

The coronavirus vaccine developed by Pfizer and BioNTech appears to protect 94% of adults over 65 years old.

As a practice we feel this data is very encouraging and would strongly recommend our patients to be prepared and ready to attend for their COVID vaccine as soon as it becomes available to them particularly in the over 65 year age groups. 

More data released from their ongoing phase three trial suggests it works equally well in people of all ages, races and ethnicities.

Although the full trial data has yet to be published, the companies say there have been no serious safety concerns. But they did notice headaches and fatigue in about 2% of volunteers given the vaccine.

In the trial, 42% of all participants are from diverse ethnic backgrounds and 41% are aged between 56 and 85 years old.

The trial, which is testing people at 150 sites in the US, Germany, Turkey, South Africa, Brazil and Argentina, will collect data on the safety and efficacy of the vaccine for another two years.

References

BBC News 18.11.2020

Local Delivery of Vaccine will probably start at some point in December or January

PLEASE DO NOT CALL US FOR INFORMATION ABOUT THE VACCINE AT THIS STAGE WE WILL CONTACT PATIENTS AS SOON AS WE KNOW ANY NEWS.

It is likely that the vaccine will be delivered from local sites in the Southwest Shropshire area.

Portcullis is working with local practices and the CCG to discuss plans for local delivery of the vaccine which are more complex than usual due to the nature of the vaccine.

We are certainly keen on a GP-led approach as we feel the GP practices in the area are experienced in the delivery of mass vaccine campaigns such as the influenza vaccine.

Priority groups for the COVID vaccine are as follows:

This interim ranking developed by the JCVI of priorities is a combination of clinical risk stratification and an age-based approach, which should optimise both targeting and deliverability. A provisional ranking of prioritisation for persons at-risk is set out below:

  1. older adults’ resident in a care home and care home workers
  2. all those 80 years of age and over and health and social care workers
  3. all those 75 years of age and over
  4. all those 70 years of age and over
  5. all those 65 years of age and over
  6. high-risk adults under 65 years of age
  7. moderate-risk adults under 65 years of age
  8. all those 60 years of age and over
  9. all those 55 years of age and over
  10. all those 50 years of age and over
  11. rest of the population (priority to be determined)

The prioritisation could change substantially if the first available vaccines were not considered suitable for, or effective in, older adults.

JCVI group in charge of covid priority groups

Opening Times

  • Monday
    08:30 until 20:00
    6-8pm Pre-booked appointments only.Call 111 for advice OOH
  • Tuesday
    08:30 until 18:30
    Call 111 for advice OOH
  • Wednesday
    08:30 until 20:00
    6-8pm Pre-booked appointments only.Call 111 for advice OOH
  • Thursday
    08:30 until 18:30
    Call 111 for advice OOH
  • Friday
    08:30 until 18:30
    Call 111 for advice OOH
  • Saturday
    CLOSED
    Open one Sat per month Pre-booked appointments only. Call 111 for advice OOH
  • Sunday
    CLOSED
    Call 111 for advice OOH